I Mab Stock Investor Sentiment

IMAB Stock  USD 1.07  0.03  2.73%   
About 62% of I Mab's investor base is looking to short. The analysis of the overall investor sentiment regarding I Mab suggests that many traders are alarmed. The current market sentiment, together with I Mab's historical and current headlines, can help investors time the market. In addition, many technical investors use I Mab stock news signals to limit their universe of possible portfolio assets.
  

I Mab Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards I Mab can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at hawaiinewsnow.com         
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration for Primar...
news
over a year ago at news.google.com         
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody ... - Marketscreener.com
Google News at Macroaxis
over a year ago at hawaiinewsnow.com         
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
news
over a year ago at thelincolnianonline.com         
I-Mab Short Interest Update
news
over a year ago at news.google.com         
GeoVax Commences Site Expansion for Phase 2 Trial of Next ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Y-mAbs Therapeutics Gets US FDA Clearance for Investigational ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023 - Marketscreener.com
Google News at Macroaxis
over a year ago at finance.yahoo.com         
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
Yahoo News
over a year ago at talkmarkets.com         
Week In Review Two China Biopharmas Announce Billion Dollar Deals
news
over a year ago at thelincolnianonline.com         
Financial Contrast Agios Pharmaceuticals and I-Mab
news
over a year ago at kalkinemedia.com         
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14BABL503
news
over a year ago at finance.yahoo.com         
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14BABL503
Yahoo News
over a year ago at hawaiinewsnow.com         
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14BABL503
news
over a year ago at news.google.com         
Kyowa acquiring gene therapy firm Orchard for up to 478M - BioWorld Online
Google News at Macroaxis
over a year ago at news.google.com         
Form 424B5 KINETA, INC.DE - StreetInsider.com
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about I Mab that are available to investors today. That information is available publicly through IMAB media outlets and privately through word of mouth or via IMAB internal channels. However, regardless of the origin, that massive amount of IMAB data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of I Mab news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of I Mab relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to I Mab's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive I Mab alpha.

I Mab Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
10/30/2024
2
I-Mab names Sean Fu as CEO
11/06/2024
3
I-Mab Reports Third Quarter 2024 Results
11/14/2024
4
I-Mab to Participate at the Piper Sandler Healthcare Conference
11/21/2024
5
IMAB Stock Drops Amidst Biotech Sector Movements
12/06/2024
6
I-Mab Announces Portfolio Prioritization of Givastomig as Lead Clinical Program
01/06/2025
7
I-Mab Biopharma Advances Precision Immuno-Oncology Programs Post-China Divestiture - TipRanks
01/13/2025

Complementary Tools for IMAB Stock analysis

When running I Mab's price analysis, check to measure I Mab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy I Mab is operating at the current time. Most of I Mab's value examination focuses on studying past and present price action to predict the probability of I Mab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move I Mab's price. Additionally, you may evaluate how the addition of I Mab to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Stocks Directory
Find actively traded stocks across global markets
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.